Screening and diagnosis of hepatocellular carcinoma

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Early diagnosis of hepatocellular carcinoma (HCC) is feasible because HCC develops in the background of well-known, readily identifiable and potentially avoidable environmental risk factors. According to the American Association for the Study of the Liver Diseases and the European Association for the Study of the Liver, patients with cirrhosis and carriers of chronic viral hepatitis are the target of surveillance to be investigated with abdominal ultrasounds (US) every 6 or 12 months. The diagnostic confirmation of a ≥2cm nodule in patients with cirrhosis detected during surveillance is possible with any imaging technique among second-generation contrast US, contrast computed tomography and gadolinium-contrast magnetic resonance imaging. HCC shows an early hyperenhanced arterial vascularization, followed by enhanced hypoattenuation (wash-out) in the late phase of imaging. In patients with a ≤2cm nodule, two imaging techniques are required for the final diagnosis, which, however, have a relatively low diagnostic sensitivity (33%). Nodules with negative imaging findings need to be investigated further with an echo-guided liver biopsy or enhanced follow-up with imaging (every 3 months) to reach a final diagnosis. The cost-effectiveness ratio of surveillance depends on multiple factors, like HCC incidence, the cost and accuracy of diagnostic tests and the costs and outcome of the therapeutic interventions.

Original languageEnglish
Pages (from-to)143-147
Number of pages5
JournalLiver International
Volume29
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2009

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Costs and Cost Analysis
Gadolinium
Chronic Hepatitis
Routine Diagnostic Tests
Cost-Benefit Analysis
Liver Diseases
Early Diagnosis
Tomography
Magnetic Resonance Imaging
Biopsy
Liver
Incidence
Therapeutics

Keywords

  • Cirrhosis
  • Computerized tomography
  • HCC
  • Magnetic resonance
  • Screening abdominal ultrasounds

ASJC Scopus subject areas

  • Hepatology

Cite this

Screening and diagnosis of hepatocellular carcinoma. / Colombo, Massimo.

In: Liver International, Vol. 29, No. SUPPL. 1, 2009, p. 143-147.

Research output: Contribution to journalArticle

@article{8b375bd4a25948a38546b930b74be130,
title = "Screening and diagnosis of hepatocellular carcinoma",
abstract = "Early diagnosis of hepatocellular carcinoma (HCC) is feasible because HCC develops in the background of well-known, readily identifiable and potentially avoidable environmental risk factors. According to the American Association for the Study of the Liver Diseases and the European Association for the Study of the Liver, patients with cirrhosis and carriers of chronic viral hepatitis are the target of surveillance to be investigated with abdominal ultrasounds (US) every 6 or 12 months. The diagnostic confirmation of a ≥2cm nodule in patients with cirrhosis detected during surveillance is possible with any imaging technique among second-generation contrast US, contrast computed tomography and gadolinium-contrast magnetic resonance imaging. HCC shows an early hyperenhanced arterial vascularization, followed by enhanced hypoattenuation (wash-out) in the late phase of imaging. In patients with a ≤2cm nodule, two imaging techniques are required for the final diagnosis, which, however, have a relatively low diagnostic sensitivity (33{\%}). Nodules with negative imaging findings need to be investigated further with an echo-guided liver biopsy or enhanced follow-up with imaging (every 3 months) to reach a final diagnosis. The cost-effectiveness ratio of surveillance depends on multiple factors, like HCC incidence, the cost and accuracy of diagnostic tests and the costs and outcome of the therapeutic interventions.",
keywords = "Cirrhosis, Computerized tomography, HCC, Magnetic resonance, Screening abdominal ultrasounds",
author = "Massimo Colombo",
year = "2009",
doi = "10.1111/j.1478-3231.2008.01938.x",
language = "English",
volume = "29",
pages = "143--147",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Screening and diagnosis of hepatocellular carcinoma

AU - Colombo, Massimo

PY - 2009

Y1 - 2009

N2 - Early diagnosis of hepatocellular carcinoma (HCC) is feasible because HCC develops in the background of well-known, readily identifiable and potentially avoidable environmental risk factors. According to the American Association for the Study of the Liver Diseases and the European Association for the Study of the Liver, patients with cirrhosis and carriers of chronic viral hepatitis are the target of surveillance to be investigated with abdominal ultrasounds (US) every 6 or 12 months. The diagnostic confirmation of a ≥2cm nodule in patients with cirrhosis detected during surveillance is possible with any imaging technique among second-generation contrast US, contrast computed tomography and gadolinium-contrast magnetic resonance imaging. HCC shows an early hyperenhanced arterial vascularization, followed by enhanced hypoattenuation (wash-out) in the late phase of imaging. In patients with a ≤2cm nodule, two imaging techniques are required for the final diagnosis, which, however, have a relatively low diagnostic sensitivity (33%). Nodules with negative imaging findings need to be investigated further with an echo-guided liver biopsy or enhanced follow-up with imaging (every 3 months) to reach a final diagnosis. The cost-effectiveness ratio of surveillance depends on multiple factors, like HCC incidence, the cost and accuracy of diagnostic tests and the costs and outcome of the therapeutic interventions.

AB - Early diagnosis of hepatocellular carcinoma (HCC) is feasible because HCC develops in the background of well-known, readily identifiable and potentially avoidable environmental risk factors. According to the American Association for the Study of the Liver Diseases and the European Association for the Study of the Liver, patients with cirrhosis and carriers of chronic viral hepatitis are the target of surveillance to be investigated with abdominal ultrasounds (US) every 6 or 12 months. The diagnostic confirmation of a ≥2cm nodule in patients with cirrhosis detected during surveillance is possible with any imaging technique among second-generation contrast US, contrast computed tomography and gadolinium-contrast magnetic resonance imaging. HCC shows an early hyperenhanced arterial vascularization, followed by enhanced hypoattenuation (wash-out) in the late phase of imaging. In patients with a ≤2cm nodule, two imaging techniques are required for the final diagnosis, which, however, have a relatively low diagnostic sensitivity (33%). Nodules with negative imaging findings need to be investigated further with an echo-guided liver biopsy or enhanced follow-up with imaging (every 3 months) to reach a final diagnosis. The cost-effectiveness ratio of surveillance depends on multiple factors, like HCC incidence, the cost and accuracy of diagnostic tests and the costs and outcome of the therapeutic interventions.

KW - Cirrhosis

KW - Computerized tomography

KW - HCC

KW - Magnetic resonance

KW - Screening abdominal ultrasounds

UR - http://www.scopus.com/inward/record.url?scp=59249107797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249107797&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2008.01938.x

DO - 10.1111/j.1478-3231.2008.01938.x

M3 - Article

VL - 29

SP - 143

EP - 147

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 1

ER -